Physician profile
Qi Feng
NPI 1659519650
$14,960.68
in general payments reported to CMS, 2019-2025
48 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $1,035 · 2021: $2,258 · 2022: $2,327 · 2023: $2,812 · 2024: $3,525 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,531 · Long Term Medical Supply Or Device Loan: $981 · Education: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,530.90 |
| Long Term Medical Supply Or Device Loan | $980.63 |
| Education | $708.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,174.63 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,083.32 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $1,018.42 | 2019-2025 | Erleada, Balversa, Akeega |
| Merck Sharp & Dohme LLC | $917.39 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Beigene USA, INC. | $747.71 | 2021-2024 | Brukinsa |
| Incyte Corporation | $702.52 | 2020-2025 | Jakafi, Monjuvi |
| Lilly USA, LLC | $691.51 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $670.78 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Rigel Pharmaceuticals, INC. | $590.21 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Astellas Pharma US INC | $551.79 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Pfizer INC. | $524.36 | 2021-2025 | |
| Eisai INC. | $495.89 | 2019-2024 | |
| Exelixis INC. | $436.23 | 2022-2025 | Cabometyx |
| Celgene Corporation | $435.92 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Glaxosmithkline, LLC. | $418.52 | 2019-2025 | Arexvy, Shingrix, Ojjaara |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $413.94 | 2019-2023 | Nplate, Lumakras |
| Abbott Laboratories | $405.25 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $380.05 | 2019-2024 | |
| Sobi, INC | $296.28 | 2022-2024 | |
| Angiodynamics, INC. | $260.48 | 2024 | Angiodynamics, Nanoknife |
| Takeda Pharmaceuticals U.S.A., INC. | $246.18 | 2021-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Alexion Pharmaceuticals, INC. | $244.80 | 2019-2023 | Ultomiris |
| Beone Medicines USA, INC. | $221.74 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $176.28 | 2023-2025 | Nerlynx |
| Gilead Sciences, INC. | $167.77 | 2021-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.87 | 2022-2025 | Gilotrif |
| Daiichi Sankyo INC. | $153.97 | 2024-2025 | Enhertu, Datroway |
| Seagen INC. | $144.10 | 2022-2023 | Padcev, Tukysa |
| Sirtex Medical INC | $134.49 | 2023 | Sir-Spheres Microspheres |
| Regeneron Healthcare Solutions, INC. | $132.39 | 2021-2023 | Libtayo |
| Genzyme Corporation | $123.70 | 2019-2025 | |
| Microvention, INC. | $117.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $116.97 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $69.76 | 2024-2025 | Pyrukynd |
| Acrotech Biopharma INC. | $69.28 | 2021-2022 | |
| Emd Serono, INC. | $69.23 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $61.64 | 2021-2025 | |
| Mirati Therapeutics, INC. | $60.36 | 2023-2024 | Krazati |
| Dova Pharmaceuticals | $59.31 | 2020-2021 | |
| Genentech USA, INC. | $45.15 | 2020-2023 | Phesgo |
| Springworks Therapeutics, INC. | $38.21 | 2025 | Gomekli, Ogsiveo |
| Shield Therapeutics INC | $24.63 | 2024 | |
| Apellis Pharmaceuticals, INC. | $22.29 | 2023 | Empaveli |
| Sanofi-Aventis U.S. LLC | $19.43 | 2020 | |
| Geron Corporation | $18.31 | 2025 | Rytelo |
| Vertical Pharmaceuticals, LLC | $16.50 | 2019 | |
| Tesaro, INC. | $16.05 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.00 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qi Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.